10X Genomics Inc
TXG
View Detailed Chart
18.610USD
+0.910+5.14%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
2.35BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+5.14%
5 Days
-7.87%
1 Month
-3.63%
6 Months
+47.00%
Year to Date
+14.10%
1 Year
+27.03%
View Detailed Chart
TradingKey Stock Score of 10X Genomics Inc
Currency: USD Updated: 2026-02-06Key Insights
10X Genomics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 59 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 18.07.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
10X Genomics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
10X Genomics Inc Highlights
StrengthsRisks
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 18.28% year-on-year.
Undervalued
The company’s latest PE is -29.84, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 125.80M shares, decreasing 10.74% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 2.63K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.35.
Analyst Rating
Based on
17
analysts
Hold
Current Rating
18.071
Target Price
+2.10%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
10X Genomics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
10X Genomics Inc Info
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
Ticker SymbolTXG
Company10X Genomics Inc
CEOSaxonov (Serge Wilson)
Websitehttps://www.10xgenomics.com/
Related Instruments
+2.98%
+0.07%
+1.60%
+2.48%
+0.31%
-1.14%
-0.05%
-2.35%
-1.78%
+2.65%
+2.59%
+2.03%
+2.01%
+2.38%
+1.74%
+0.16%
+0.78%
+1.72%
+0.59%
-2.02%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
69601.180
-368.950 (-0.53%)
282.580
+22.390 (+8.61%)
2102.820
+51.090 (+2.49%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
